RxDoctor Payments Data

John Nwabugwu

Psychiatric/Mental Health · Plymouth, MNNPI 1215530571

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations.

$374in general payments, 2019–2025

Across 21 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuronetics, Inc.$76
  • Supernus Pharmaceuticals, Inc.$62
  • Tris Pharma Inc$40
  • Tempus AI, Inc$29
  • Corium, LLC$20
  • E.r. Squibb & Sons, L.L.C.$19
  • plus $127 from 9 others

What the payments were for

  • Food & beverage$374100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$374 in reported general payments places this provider in the 85th percentile of 407 psychiatric/mental health providers in Minnesota.

See all psychiatric/mental health providers in Minnesota

Medicare billing

Part B allowed, 2024
$11,868
Medicare patients
20
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methylphenidate Hcl11$7,462
BelsomraSuvorexant11$4,718
VyvanseLisdexamfetamine Dimesylate11$4,212
Vilazodone Hcl11$1,148
Venlafaxine Hcl ErVenlafaxine Hcl38$780
Buspirone Hcl42$672
Bupropion XlBupropion Hcl33$615
Divalproex Sodium31$614
Clonazepam18$601
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine18$573
Lamotrigine15$536
Trazodone Hcl49$465
Olanzapine31$440
Hydroxyzine Hcl24$425
Sertraline Hcl49$405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckBelsomra$15$4,71811 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$15$4,21211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 407 psychiatric/mental health providers in Minnesota.

Other psychiatric/mental health in Plymouth

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →